InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals' Revenue history runs 5 years deep, the most recent figure standing at $820188.0 for Q4 2025.

• On a quarterly basis, Revenue fell 26.22% year-over-year to $820188.0 in Q4 2025; TTM through Dec 2025 was $4.5 million, a 6.73% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, up 7.5% from the prior year.
• Revenue slipped to $820188.0 in Q4 2025 per INM's latest filing, from $1.1 million in the prior quarter.
• Across five years, Revenue topped out at $2.3 million in Q2 2023 and bottomed at $265092.0 in Q4 2021.
• The 5-year median for Revenue is $1.1 million (2024), against an average of $999769.6.
• Across the five-year window, Revenue surged 348.96% in 2023 and tumbled 44.48% in 2024, its largest moves.
• Year by year, Revenue stood at $265092.0 in 2021, then surged by 77.22% to $469783.0 in 2022, then jumped by 163.99% to $1.2 million in 2023, then retreated by 10.36% to $1.1 million in 2024, then declined by 26.22% to $820188.0 in 2025.
• Per Business Quant, the three latest INM Revenue figures stand at $820188.0 (Q4 2025), $1.1 million (Q3 2025), and $1.3 million (Q2 2025).